{"ticker": {"uuid": "d66d9272-be3e-4daf-b8ca-580b52252cad", "symbol": "HROW", "name": "Harrow Health Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "Harrow Inc (HROW) Shares Surge 3.9% -- What GF Score of 81 Tells Investors", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNTXltSHpNRmxkMW40SzQtOFZtMHVqYTNZNlRPOVRabmt0My1GZHZWR002OWhmVGJaRGNsVnliT212cnZsU2FQSFB0LWFsMU5QNFZWaTFuMUpabzVpZ3QyU19aYzZHWk94ejBJcVYwOUxkTTlhcDZaR01ha0tZVDNtRnZEWGxRcTlIT0J5YXN0U2wzVjFLVFZnY1FZbm4zWWRYOFhzWGpCdkhjRDdEQm84aEdSWGMxUTFYOUE?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-16T00:33:48+00:00", "published_display": "16 Jul 2026 00:33", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harrow: Debt-Fueled Liquidity Masks An Operating Cash Problem (NASDAQ:HROW)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOSE5MMVN0ZmN1aFZyV25nSFI5T3FyY3NKY0d3WkMzRFRIdUpnLUxZZUMtZFlvbllHMDhleXRTdkVPSnpwR3JTajBVNXd0VVk4bldrV3FNLTdnMHdCSzg3X2R1NGdWSks3TzZDNXJhV20zS0Q5X1JSSERyb1VOenp5OXZ0RzBYQU1vZlJWUjI1VWk1anRtYmNYaml5TUtHdkZSaldZ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-15T17:58:50+00:00", "published_display": "15 Jul 2026 17:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Investors May Respond To Harrow (HROW) Taking Over BYOOVIZ US Commercialization And Ophthalmic Biosimilars", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-10T07:59:07+00:00", "published_display": "10 Jul 2026 07:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Are Optimistic We'll See A Profit From Harrow, Inc. (NASDAQ:HROW)", "summary": "Analysts are predicting that Harrow, Inc. (NASDAQ:HROW) will soon become profitable, with a significant increase in revenue expected over the next few years. The average analyst price target suggests a substantial upside for the stock. However, investors should consider the compa", "url": "https://news.futunn.com/en/post/75781058/analysts-are-optimistic-we-ll-see-a-profit-from-harrow", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-07-09T12:11:01", "published_display": "09 Jul 2026 12:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Harrow, Inc. \u2013 NASDAQ:HROW", "summary": "This article provides financial information for Harrow, Inc. (NASDAQ: HROW) on TradingView, specifically focusing on its Price to Earnings Forward metric. It indicates that the market is closed, with no current trades. The content is primarily a navigation and site structure page", "url": "https://www.tradingview.com/symbols/NASDAQ-HROW/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T05:10:03", "published_display": "05 Jul 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harrow Announces Commercial Launch of BYOOVIZ\u00ae in the United States", "summary": "Harrow announces the commercial launch of BYOOVIZ\u00ae (ranibizumab-nuna) in the United States, an FDA-approved interchangeable biosimilar referencing LUCENTIS. This launch expands Harrow's retina portfolio and strengthens its position in the rapidly growing retinal biologics market.", "url": "https://www.sahmcapital.com/news/content/harrow-announces-commercial-launch-of-byooviz-in-the-united-states-2026-07-01", "source_name": "Sahm", "published_at": "2026-07-03T03:40:10", "published_display": "03 Jul 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harrow relaunches biosimilar Byooviz in the US", "summary": "Harrow Inc. has re-launched BYOOVIZ (ranibizumab-nuna) in the U.S. commercial market, stemming from a partnership with Samsung Bioepis Co., Ltd. BYOOVIZ is an intravitreally-administered injection for treating wet age-related macular degeneration, macular edema following retinal ", "url": "https://glance.eyesoneyecare.com/stories/2026-07-02/harrow-relaunches-biosimilar-byooviz-in-the-us/", "source_name": "Eyes On Eyecare", "published_at": "2026-07-02T21:10:10", "published_display": "02 Jul 2026 21:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Harrow, Inc. \u2013 NASDAQ:HROW", "summary": "The article references the \"Price to book forward\" for Harrow, Inc. (NASDAQ: HROW) and appears to be a financial data page from TradingView. It provides basic stock information and navigation elements, but the substantive financial data itself is not displayed in this snippet. Th", "url": "https://www.tradingview.com/symbols/NASDAQ-HROW/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T14:39:53", "published_display": "02 Jul 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Harrow, Inc. \u2013 NASDAQ:HROW", "summary": "This article provides the \"Price to sales forward\" metric for Harrow, Inc. (NASDAQ: HROW) as presented on TradingView. It indicates that the market was closed at the time of viewing, with no trades reported. The content also briefly lists various financial data sources and featur", "url": "https://www.tradingview.com/symbols/NASDAQ-HROW/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T14:10:11", "published_display": "02 Jul 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Harrow, Inc. \u2013 NASDAQ:HROW", "summary": "This article displays the \"Enterprise value to EBITDA forward\" for Harrow, Inc. (NASDAQ:HROW) on TradingView. It shows that the value is not available (\"No trades\") and provides information about the data sources used on the platform. The main focus is presenting a specific finan", "url": "https://www.tradingview.com/symbols/NASDAQ-HROW/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T05:41:50", "published_display": "02 Jul 2026 05:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Samsung Bioepis Relaunches BYOOVIZ\u00ae (ranibizumab-nuna) in the United States in Partnership with Harrow", "summary": "Samsung Bioepis has relaunched BYOOVIZ\u00ae (ranibizumab-nuna), an FDA-approved biosimilar to LUCENTIS, in the United States through a new partnership with Harrow. This relaunch aims to enhance access to critical retinal disease treatments like those for Wet Age-Related Macular Degen", "url": "https://www.businesswire.com/news/home/20260701576499/en/Samsung-Bioepis-Relaunches-BYOOVIZ-ranibizumab-nuna-in-the-United-States-in-Partnership-with-Harrow", "source_name": "Business Wire", "published_at": "2026-07-02T02:40:50", "published_display": "02 Jul 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Harrow, Inc. \u2013 NASDAQ:HROW", "summary": "The article provides financial information for Harrow, Inc. (NASDAQ: HROW), specifically its enterprise value to revenue forward. It appears to be a stub or a section from a larger financial data platform, showing the company's ticker, market, and a period-specific value with cha", "url": "https://www.tradingview.com/symbols/NASDAQ-HROW/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T00:47:37", "published_display": "02 Jul 2026 00:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harrow brings an interchangeable eye-drug biosimilar to U.S. retina care", "summary": "Harrow (Nasdaq: HROW) has launched BYOOVIZ (ranibizumab-nuna) in the U.S., an FDA-approved interchangeable biosimilar referencing LUCENTIS for various retinal conditions like Wet AMD. This launch, following an exclusive commercialization agreement with Samsung Bioepis, expands Ha", "url": "https://www.stocktitan.net/news/HROW/harrow-announces-commercial-launch-of-byooviz-in-the-united-jam75vn55hot.html", "source_name": "Stock Titan", "published_at": "2026-07-01T14:39:53", "published_display": "01 Jul 2026 14:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harrow Expands Retina Portfolio With US Launch of Byooviz", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/harrow-expands-retina-portfolio-us-120331323.html", "source_name": "MT Newswires", "published_at": "2026-07-01T12:03:31+00:00", "published_display": "01 Jul 2026 12:03", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A first FDA-approved eye biosimilar returns to U.S. sales", "summary": "Samsung Bioepis has relaunched BYOOVIZ (ranibizumab-nuna) in the US in partnership with Harrow, making the FDA-approved ophthalmology biosimilar referencing LUCENTIS available again. BYOOVIZ was the first ophthalmology biosimilar approved by the FDA in 2021 and received interchan", "url": "https://www.stocktitan.net/news/HROW/samsung-bioepis-relaunches-byooviz-ranibizumab-nuna-in-the-united-bqveabvqfqe4.html", "source_name": "Stock Titan", "published_at": "2026-07-01T11:11:37", "published_display": "01 Jul 2026 11:11", "sentiment": "positive", "sentiment_pct": 74, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Grow Funds\u2019 Exit and Weaker Earnings Recast Harrow\u2019s (HROW) Growth Narrative and Governance Choices", "summary": "Harrow, Inc.'s recent annual meeting approved director nominees and executive compensation, but Grow Funds' exit and disappointing earnings have cast doubt on the company's growth narrative. Investors are now more closely scrutinizing Harrow's ability to execute on product launch", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-hrow/harrow/news/how-grow-funds-exit-and-weaker-earnings-recast-harrows-hrow", "source_name": "Simply Wall Street", "published_at": "2026-06-25T23:09:33", "published_display": "25 Jun 2026 23:09", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harrow, Inc. Actuals & Estimates (NASDAQ:HROW)", "summary": "This article provides an overview of Harrow, Inc. (HROW) stock, including its current price, market capitalization, historical performance, and financial estimates. It details analyst forecasts, past earnings reports, future earnings dates, and revenue figures, emphasizing that t", "url": "https://www.tradingview.com/symbols/NASDAQ-HROW/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T16:09:12", "published_display": "25 Jun 2026 16:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HROW Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Harrow, Inc. (HROW) stock, including its current price, historical highs and lows, and analyst predictions for 2027. It also details financial metrics such as market capitalization, recent earnings, revenue, EBITDA, and upcoming earnings repor", "url": "https://www.tradingview.com/symbols/NASDAQ-HROW/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T14:41:11", "published_display": "25 Jun 2026 14:41", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harrow (HROW) director granted 5,248 restricted stock units as compensation", "summary": "Harrow, Inc. director Lauren P. Silvernail was granted 5,248 restricted stock units (RSUs) as compensation for her services. These RSUs will vest in equal quarterly installments over one year, contingent on her continued service with the company. The shares underlying these RSUs ", "url": "https://www.stocktitan.net/sec-filings/HROW/form-4-harrow-inc-insider-trading-activity-f57206ccfe0d.html", "source_name": "Stock Titan", "published_at": "2026-06-24T04:10:26", "published_display": "24 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GROW Small Cap Equity Fund Covered Its Position in Harrow (HROW) in Q1", "summary": "The GROW Small Cap Equity Fund covered its position in Harrow, Inc. (HROW) during Q1 2026, citing a disconnect between high street earnings expectations and the company's underlying growth. While the fund acknowledged Harrow's long-term potential, its conviction shifted towards A", "url": "https://www.insidermonkey.com/blog/grow-small-cap-equity-fund-covered-its-position-in-harrow-hrow-in-q1-1787389/", "source_name": "Insider Monkey", "published_at": "2026-06-23T08:06:00", "published_display": "23 Jun 2026 08:06", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Harrow Health Inc For: 22 June By Investing.com", "summary": "This article announces a Form 4 filing for Harrow Health Inc., dated June 22. It briefly mentions the company's stock symbol, HROW, and its -1.07% performance, alongside other financial market data and news headlines.", "url": "https://uk.investing.com/news/stock-market-news/form-4-harrow-health-inc-for-22-june-93CH-4739325", "source_name": "Investing.com UK", "published_at": "2026-06-23T00:40:51", "published_display": "23 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harrow (HROW) director Adrienne Graves receives 5,248 RSUs as compensation grant", "summary": "Harrow, Inc. (HROW) director Adrienne L. Graves has been granted 5,248 Restricted Stock Units (RSUs) as compensation for her services. These RSUs will vest in equal quarterly installments over one year, contingent on her continued service. The underlying shares will not be delive", "url": "https://www.stocktitan.net/sec-filings/HROW/form-4-harrow-inc-insider-trading-activity-ef98c155356c.html", "source_name": "Stock Titan", "published_at": "2026-06-22T23:40:51", "published_display": "22 Jun 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] HARROW, INC. Insider Trading Activity", "summary": "HARROW, INC. director Perry J. Sternberg reported the acquisition of 5,248 restricted stock units (RSUs) as compensation. These RSUs vest in equal quarterly installments over one year and will only be delivered as common shares after his service with the company ends. This transa", "url": "https://www.stocktitan.net/sec-filings/HROW/form-4-harrow-inc-insider-trading-activity-7906527569af.html", "source_name": "Stock Titan", "published_at": "2026-06-22T23:40:50", "published_display": "22 Jun 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 8K Harrow Health Inc For: 22 June By Investing.com", "summary": "This article reports on the filing of a Form 8K by Harrow Health Inc. for June 22nd. It provides the stock symbol HROW and mentions its current performance. The content is brief and serves primarily as an announcement of the filing.", "url": "https://ca.investing.com/news/stock-market-news/form-8k-harrow-health-inc-for-22-june-93CH-4700525", "source_name": "Investing.com Canada", "published_at": "2026-06-22T22:11:53", "published_display": "22 Jun 2026 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harrow elects directors and approves executive compensation at annual meeting By Investing.com", "summary": "Harrow, Inc. (NASDAQ: HROW) shareholders elected four directors to its board, approved executive compensation, and ratified Deloitte & Touche LLP as its accounting firm during the 2026 Annual Meeting of Stockholders. The company's shares have seen significant gains over the past ", "url": "https://za.investing.com/news/stock-market-news/harrow-elects-directors-and-approves-executive-compensation-at-annual-meeting-93CH-4337430", "source_name": "Investing.com South Africa", "published_at": "2026-06-22T22:11:52", "published_display": "22 Jun 2026 22:11", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harrow elects directors and approves executive compensation at annual meeting", "summary": "Harrow, Inc. (NASDAQ: HROW) held its 2026 Annual Meeting where shareholders elected four directors to the board, approved executive compensation on an advisory basis, and ratified Deloitte & Touche LLP as its independent accounting firm for 2026. The company has seen a 10% stock ", "url": "https://m.investing.com/news/sec-filings/harrow-elects-directors-and-approves-executive-compensation-at-annual-meeting-93CH-4752421?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-22T11:39:46", "published_display": "22 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harrow (HROW) investors back all 2026 director, pay and auditor proposals", "summary": "Harrow, Inc. shareholders approved all proposals at their 2026 annual meeting, including the election of four directors, advisory approval of executive officer compensation, and the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the", "url": "https://www.stocktitan.net/sec-filings/HROW/8-k-harrow-inc-reports-material-event-bd517e45a284.html", "source_name": "Stock Titan", "published_at": "2026-06-22T11:39:46", "published_display": "22 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spotlight On Harrow And 2 Other Growth Stocks With Strong Insider Backing", "summary": "This article highlights Harrow (HROW), Alphatec Holdings (ATEC), and AvePoint (AVPT) as growth stocks with significant insider ownership, suggesting strong confidence from management. Harrow, an eyecare pharmaceutical company, expects substantial revenue growth and future profita", "url": "https://simplywall.st/stocks/us/software/nasdaq-avpt/avepoint/news/spotlight-on-harrow-and-2-other-growth-stocks-with-strong-in", "source_name": "Simply Wall Street", "published_at": "2026-06-18T11:40:17", "published_display": "18 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harrow Inc (HROW) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Harrow Inc (HROW) holds a stable financial status with a score of 7.49, ranking 117th in the Pharmaceuticals industry. While its operating efficiency is high, the company reported a year-over-year revenue decrease of 7.59% and a significant net profit decrease of 55.24% in its la", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-hrow/financial-health", "source_name": "TradingKey", "published_at": "2026-06-17T09:40:05", "published_display": "17 Jun 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harrow Inc (HROW) Institutional Confidence", "summary": "This article analyzes Harrow Inc.'s (HROW) institutional confidence, noting its current shareholding score of 5.00, placing it 73rd out of 157 in the Pharmaceuticals industry. Institutional shareholding has increased to 66.17% quarter-over-quarter. Private Capital is the largest ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-hrow/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T09:11:04", "published_display": "17 Jun 2026 09:11", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can Harrow\u2019s (HROW) VERKAZIA Relaunch Redefine Its Niche Ophthalmic Strategy?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOZUpsSU9ScmQxNC1tMDVhZGJTZG14YllxSXVHYWs5bkF4QUM5YVNiVzZFQzNXWEk5T3hNTk1fTHNYRnQ1RFlqem9KSmdnWERudFZETThoWEZHREpYUHZnN3dCMUhxTEF1cVJOeElXVTVha0JfYS1kdmRDY05qdmJoQ0R4QUZraUR3c3NVYUIxaTZnNGJTRXZRZ2tFWkJSenhHLTFLTVJqQ2dtaDA?oc=5", "source_name": "Market source", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HROW Stock Rises on Relaunch of Ophthalmology Drug Verkazia in the US", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQalJfMUFSZ3BRUHNsdUZ3RmlqRWNHMnRFYXpCT2xWUDdNUW9WQS1Ba05nLVVaaEdZTkFGS01HTm9yMUlvWUo4MzBXQXc1SldiYUtYSXF1MDJkcTYwUk8ycHhXdHJCWGhWZWtmaUJBdWxvOW9adjAwOURtT2x5VHpPYUhRd3ZDeVNyYVhVT1lLNU5fLXBZQ05JbDhueGpzaVp0RUFQMGtsOXhFZ1V5cmZV?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harrow Re-Launches VERKAZIA\u00ae (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/harrow-launches-verkazia-cyclosporine-ophthalmic-110000502.html", "source_name": "GlobeNewswire", "published_at": "2026-06-10T11:00:00+00:00", "published_display": "10 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Does Cantor Fitzgerald Think About Harrow (HROW) After Cutting Its Price Target?", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/does-cantor-fitzgerald-think-harrow-214353759.html", "source_name": "Insider Monkey", "published_at": "2026-06-04T21:43:53+00:00", "published_display": "04 Jun 2026 21:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harrow to Present at William Blair\u2019s 46th Annual Growth Stock Conference", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/harrow-present-william-blair-46th-110000356.html", "source_name": "GlobeNewswire", "published_at": "2026-05-27T11:00:00+00:00", "published_display": "27 May 2026 11:00", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why B.Riley Reduced Harrow, Inc. (HROW) Price Target Despite Long-Term Optimism", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxOQy1DWHFQcFBfVWtxUHN3SG5sMFdQLVR2SGxFUjNwNFdYLWZRdk9FZVhfX3FWd0J0YlBkUGozLWgzTUczREhJNXZZc1VST3J4RS1MNkJQMk1ScWVrWHdfblFSRkExMGU5YzhfMy1LU0VVaDBHQXZMSU50WldHRXNsT0ZyZHZGdFpHVV9YVVJ0bGk4LUtYb3c?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Harrow (HROW) Narrative Is Shifting As Analysts Recut Targets Yet Stay Positive", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOdEFtdk1UMUxtTzJLaVdXYl9EY29xaXcyU1hfMzlqc2U4Ylp3bkpmTGFCOXJ0THByZkFfTWZObjVTcl9KYXBnN1dPaWFCRzZOX0h1TmtfQVZIbjVhUEM1YmMtemV0ZWxNRTA1ekZxSjJpSzY0UW5ZTkViZHk2Y1gwTEJLS1VXMXo2dGo1UXJvdGtUMm9mbU9BX0ZBSU9BbnFh?oc=5", "source_name": "Market source", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Opaleye entities report 7.61% stake in Harrow (NASDAQ: HROW)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxNZFdDTkZpdzBWOUdYeWtfNnUxeUoxWHZyUk5UQmh3UWJpWUo4cC1PX3FDVkhDZjl0cGx1eXNRemIxNkZHV0ljS0pNZEw2TzJaMjlHR1F1SnAzVXZUeVZERXFkRmJrLS1aLUs1SE1IdndyQ2QySDZ2Y3gycmJHMlFVWVVwcWd1N3ZWbWdXUHgxVWp4ZlZHaHRMUk1rVElFNWZ3QXJlckI1WmI0cTdfTkFjdXpFVDJlU2dheHJsZ0VLUDZvY0U?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harrow (HROW) Reports Q1 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOb2VzbU54QVdJUEhIUEJUSmNCWmhYS3ZsT1NUQkk5ZTlCWFhlRVdFQ0hieWNlalNWX2QyalZnVVRyVGFIZDJvcTJMLWVIZ0ZROXM5ZW84Z1FGNVF2Z25yTjBpUzd0UjVFdmZVUXZ0VXV1aVdQTVBmdjBRRWFBSXpyaXZWUmJSSDJvVnY2VGVwQzRWOVRwUVhYQVVoWFM?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harrow Inc. (HROW) stock falls on Q1 2026 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxOMXVqVWc1eHlqejRrNDJ3c2cwZ1ZNQXNKVUZhanp3SEtDM3FGQVhIdF93WVBzTF9ZZVh0b2RlaGlHNWNxSUNkZkNFbGJsVjEtUWJvd2cyYTdpQ3E5QmxTZGt5QVJfWWZhbDlNZTlRd1NadllyZmpLTUIxWjRJc0wtazZ2aENoTFFUTzRfRGY3aEI?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Harrow (HROW) Pricing Reflect Its 65.5% One Year Surge And DCF Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNelVNS01NUUU2amx5ZTE5eEJITjNpNlFSNjdmd1Y0NDI3QVpDdDY2LXVDNGdReVROeGVheWVzVU5iX1d0RnNIcGJaSmdkYUhSQk9DamFGb0hhclV5UHJfZGNrMVE1R2oyWFRoT0ZtNTRldVNkUUdwMEdFTHJmdU5UOXNvWWFlNlJRN29lZmVmYlZhUmhzbWFLUkNIQQ?oc=5", "source_name": "Market source", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harrow Inc (NASDAQ:HROW) Screens as a Strong Growth Stock with a Bullish Technical Setup", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxPNXFlbzFYZ0paM2hlRjg4YW9TWjQ3YlBkdm03emRYZWh1Z2RtSWZGUEFmajVZVFJrMEJ1UHp5OWhsRkVnS0JyLXptTFBNc0lxZTZXVXNrVG0yM2psMEpmbW1XS0h0d1ItYmNvOWFvc0VUbDBBX2RXMFQ4YS1lNjJNM3JqY3lFbDBVeDZmbm5oRTI3dmxybk52NDRaRnN1T3Y5Y3JSaEZlck9BN3RXV3FLNDFLR3ZHR0d1VzNQYTBCdEtnN3lUa0hKOXJMSUlqZ0ZUUXpJ?oc=5", "source_name": "ChartMill", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 95, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Estimate Harrow (HROW) to Report a Decline in Earnings: What to Look Out for", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQZWl6LXZuTVc5b2dFRTdfTGViNUZWTi1DTGhWaEZKc1l4WE4zLVdyM1FjTi0zc1lqUTdGOF9LSF9Nb1JLamJDUFFhcXNyLUFrMTg0MFVQbHRDc2hHYjNBT3dOV2xxS05JNXRFTW5zQmp4WW5RTW9DR1Y2VVhZV3hWdFRkb0oxNk8wQ3A3UFdhYTBfS01XRXhjQk5tV2VtY3MxVjNz?oc=5", "source_name": "Market source", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Harrow, Inc. (HROW) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxONDFMWlhjRkExd003OFA0b2xGN1I3cFQyWGFIYUtZb1pCODctclBhdzZZVnBjU2dKSVFlSEc3NDYwa3hBODVZLXhnczJEZ1ZxTzhGQnVBWEVsMkw2VU9sUE05b3lqSUhMeWRnZ24yTFpsSUJXNzYzb1kxbWRGU1pSZTJBUFFWc3JDbThoVV84X1dIWFZuYkE?oc=5", "source_name": "Market source", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harrow shifts U.S. eye drug distribution to LogiCare3PL in 4 weeks", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNVDdVZWRyNGtkY0k0TjdTTzJTVERFSlVva000MjBJX1NGd3lYR0d4RXMtZjQyZnIzN3pfaDZmRGhBWmNkVmpsNXNwM2pyMC1hb0tESnd5LTlXaTRwOHNEUDlMLVhraGVNMGF6MUlSZmdYby1MYWhZWEhWcHB6NVNLQjg5dEdzRmpMU3FFR2ZRR2o2cy1oQ05qdTl0T1lPdEoxaW5oZzln?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Health Insurance Providers Stocks\u2019 Q4 Earnings: Alignment Healthcare (NASDAQ:ALHC) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNT01mVGxMZ0dTU1BFZll2Wm5Bekc1STJkajdhWGFYMmJGUktiVFZGN2k4b3ZobDNVbW5IejF6dGZYWERRR1g0aHhrcUJnZ09PeU1sb3FISTZjWjlVMmFMMEhVdERvU0k0a2tIQmhkSTB4bzFaN1NYbi1xekk1OHk5TE82WlpkVmVHZ2VNY25OejQ2MHhsRVNsbngydG5Rd29TcmJuLVI3YlU?oc=5", "source_name": "Market source", "published_at": "2026-04-03T07:00:00+00:00", "published_display": "03 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HARROW INC (NASDAQ:HROW): A GARP Stock with Strong Growth at a Reasonable Price", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPd204aGxqTzlERDY0dWFURFpBNnZia3lVU1dQeHZ6VXdIQ2o5UmNtcVNKWlY0M0V6RkxMT1JaR1JHMjI1aFYwSVZFVVkyTEJyTE94c21zSGpDcVBRYnpGNVE4TFJjb2FYTGZnNDJLWEhTcFBsTEZLWWV3THYzSUpGd0ctcFQyYnQ1UEZtb2tMVDk1cS0zQmc3Tno3Rmd0R3pSNzM3VjNUWGp3SXk4bzVicU1WMW1MNnAzYXprZWtndHRQSjJCUXc?oc=5", "source_name": "ChartMill", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harrow (HROW) Misses Q4 Earnings Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxNcTFoTjMyYWRpX2xhLU1MRWVSVmlTbUhON0JSZVo0cjdkdVUxWjVJbWNMTEU1aW1CX0dpSGNHNEJMVmcwLVVYSmwxbGtkSFNaeWR5OHdRYUVoSnFCUWdLRDdSeEIwbmNnX01NekJRS1N0NjVWdFc4aUpORXFUdWg2dFJn?oc=5", "source_name": "Market source", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harrow Inc. (HROW) Stock Falls on Q4 2025 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxOZ2hzZWJmamE2S05DUDN5c1FvTHlTcVdiX0dCZVN0aTg5MlVqRXJDeVo0bk1NcUo3WEI5OVJ2enBRVk54eHc3cldGYkNibnRydU5uUnk1ZXhCWGRTZ1dMNHdnWVh6Tm15Smo1Y2pPN250MUFUYnMyY2ZKdHdxZU9PTFBTdnY0NHhlZkU3cUdqZjM?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harrow Announces Availability of Fortisite\u2122 Formulations for In-Office Use", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOc2Vibk1tSzVJNG9RbVhaVkxDcWdMNWZOQjFLTzRjdGpvV3czR1pwcmZGTVVqeUpJdVJwOXhnMEUtMG5BNlJHblNLWFJWNS1JYnFXRGZyVzhIc0V6TzNNUlYyUnlwbHdMY0ZCNHBGU1N5bHh4OUx2bGFiNjdEWjVzT195NUpOakZCNENCNlpkVTY0MDc0dGY2S21vX3FGc1RBYnN5T1drSUROMVNqekxXcXItT2ZsZWQwTERjdDRUNDFoT21xRDktTTVB?oc=5", "source_name": "Business Wire", "published_at": "2023-01-05T08:00:00+00:00", "published_display": "05 Jan 2023 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harrow Secures Capital to Close Recently Announced Acquisition", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOWndtLTZpUThTYVU4T043cG9fcFVHTHR4ZTd4MUhVRVdRUWxxdDgyY0F1RWNtMGF5eV9UdzJ2cEk4V1E4U0tKU09CZFYwaTFaWi1pajBlaEVGZjhPbHYwU2pJUkZ3bnJodDF5X21HN3JzOGhHTkY1ZjZ4X21zdk5Sb09VX3FCWmRpTG5GeWFzN1Q2RWRMS1lWWldSeGt1N1BseDNsUkNyakxnUFFkLTdZbTNvV2x6cm9qc01R?oc=5", "source_name": "Business Wire", "published_at": "2022-12-16T08:00:00+00:00", "published_display": "16 Dec 2022 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harrow Health Announces Second Quarter 2022 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQaWRhQTdmSF85Ri13U3hwcHdxVVJxUDF2UjJORWtVVjlteUpUZUxiS2hidzZNa01NbHRPdWtJX1RrbmdOS0dQcmwwb2VSUVNOUzhPMVIxMnRnZXk2WDd3aUEydDU3U0lyVVU3VFNCNndXQ3dDNEdwdDJtdmZfdHVmLXB3MlRaOHdKZ2ttLTQxeTU4RjVhb1VKMzhUMDAyRFFQQWRzejRac3VBM01fUmhSVVFuQ2tRUU9uY2c?oc=5", "source_name": "Business Wire", "published_at": "2022-08-09T07:00:00+00:00", "published_display": "09 Aug 2022 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harrow (HROW) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE5HaW44bC1xNUpTRDNLU0Z1bWdqNDhWQWlSNGpsRWpEVnZ3VUtiY1Y3amw4UjhLTHJ6S3F2UVNwM2R4V0h5dU1vYzhYaVRybDRzcVRzT1owbjJPUQ?oc=5", "source_name": "MarketBeat", "published_at": "2019-02-02T02:56:21+00:00", "published_display": "02 Feb 2019 02:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Harrow Inc (HROW) Shares Surge 3.9% -- What GF Score of 81 Tells Investors", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNTXltSHpNRmxkMW40SzQtOFZtMHVqYTNZNlRPOVRabmt0My1GZHZWR002OWhmVGJaRGNsVnliT212cnZsU2FQSFB0LWFsMU5QNFZWaTFuMUpabzVpZ3QyU19aYzZHWk94ejBJcVYwOUxkTTlhcDZaR01ha0tZVDNtRnZEWGxRcTlIT0J5YXN0U2wzVjFLVFZnY1FZbm4zWWRYOFhzWGpCdkhjRDdEQm84aEdSWGMxUTFYOUE?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-16T00:33:48+00:00", "published_display": "16 Jul 2026 00:33", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harrow: Debt-Fueled Liquidity Masks An Operating Cash Problem (NASDAQ:HROW)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOSE5MMVN0ZmN1aFZyV25nSFI5T3FyY3NKY0d3WkMzRFRIdUpnLUxZZUMtZFlvbllHMDhleXRTdkVPSnpwR3JTajBVNXd0VVk4bldrV3FNLTdnMHdCSzg3X2R1NGdWSks3TzZDNXJhV20zS0Q5X1JSSERyb1VOenp5OXZ0RzBYQU1vZlJWUjI1VWk1anRtYmNYaml5TUtHdkZSaldZ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-15T17:58:50+00:00", "published_display": "15 Jul 2026 17:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Investors May Respond To Harrow (HROW) Taking Over BYOOVIZ US Commercialization And Ophthalmic Biosimilars", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-10T07:59:07+00:00", "published_display": "10 Jul 2026 07:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Are Optimistic We'll See A Profit From Harrow, Inc. (NASDAQ:HROW)", "summary": "Analysts are predicting that Harrow, Inc. (NASDAQ:HROW) will soon become profitable, with a significant increase in revenue expected over the next few years. The average analyst price target suggests a substantial upside for the stock. However, investors should consider the compa", "url": "https://news.futunn.com/en/post/75781058/analysts-are-optimistic-we-ll-see-a-profit-from-harrow", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-07-09T12:11:01", "published_display": "09 Jul 2026 12:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Harrow, Inc. \u2013 NASDAQ:HROW", "summary": "This article provides financial information for Harrow, Inc. (NASDAQ: HROW) on TradingView, specifically focusing on its Price to Earnings Forward metric. It indicates that the market is closed, with no current trades. The content is primarily a navigation and site structure page", "url": "https://www.tradingview.com/symbols/NASDAQ-HROW/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T05:10:03", "published_display": "05 Jul 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harrow Announces Commercial Launch of BYOOVIZ\u00ae in the United States", "summary": "Harrow announces the commercial launch of BYOOVIZ\u00ae (ranibizumab-nuna) in the United States, an FDA-approved interchangeable biosimilar referencing LUCENTIS. This launch expands Harrow's retina portfolio and strengthens its position in the rapidly growing retinal biologics market.", "url": "https://www.sahmcapital.com/news/content/harrow-announces-commercial-launch-of-byooviz-in-the-united-states-2026-07-01", "source_name": "Sahm", "published_at": "2026-07-03T03:40:10", "published_display": "03 Jul 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harrow relaunches biosimilar Byooviz in the US", "summary": "Harrow Inc. has re-launched BYOOVIZ (ranibizumab-nuna) in the U.S. commercial market, stemming from a partnership with Samsung Bioepis Co., Ltd. BYOOVIZ is an intravitreally-administered injection for treating wet age-related macular degeneration, macular edema following retinal ", "url": "https://glance.eyesoneyecare.com/stories/2026-07-02/harrow-relaunches-biosimilar-byooviz-in-the-us/", "source_name": "Eyes On Eyecare", "published_at": "2026-07-02T21:10:10", "published_display": "02 Jul 2026 21:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Harrow, Inc. \u2013 NASDAQ:HROW", "summary": "The article references the \"Price to book forward\" for Harrow, Inc. (NASDAQ: HROW) and appears to be a financial data page from TradingView. It provides basic stock information and navigation elements, but the substantive financial data itself is not displayed in this snippet. Th", "url": "https://www.tradingview.com/symbols/NASDAQ-HROW/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T14:39:53", "published_display": "02 Jul 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Harrow, Inc. \u2013 NASDAQ:HROW", "summary": "This article provides the \"Price to sales forward\" metric for Harrow, Inc. (NASDAQ: HROW) as presented on TradingView. It indicates that the market was closed at the time of viewing, with no trades reported. The content also briefly lists various financial data sources and featur", "url": "https://www.tradingview.com/symbols/NASDAQ-HROW/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T14:10:11", "published_display": "02 Jul 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Harrow, Inc. \u2013 NASDAQ:HROW", "summary": "This article displays the \"Enterprise value to EBITDA forward\" for Harrow, Inc. (NASDAQ:HROW) on TradingView. It shows that the value is not available (\"No trades\") and provides information about the data sources used on the platform. The main focus is presenting a specific finan", "url": "https://www.tradingview.com/symbols/NASDAQ-HROW/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T05:41:50", "published_display": "02 Jul 2026 05:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Samsung Bioepis Relaunches BYOOVIZ\u00ae (ranibizumab-nuna) in the United States in Partnership with Harrow", "summary": "Samsung Bioepis has relaunched BYOOVIZ\u00ae (ranibizumab-nuna), an FDA-approved biosimilar to LUCENTIS, in the United States through a new partnership with Harrow. This relaunch aims to enhance access to critical retinal disease treatments like those for Wet Age-Related Macular Degen", "url": "https://www.businesswire.com/news/home/20260701576499/en/Samsung-Bioepis-Relaunches-BYOOVIZ-ranibizumab-nuna-in-the-United-States-in-Partnership-with-Harrow", "source_name": "Business Wire", "published_at": "2026-07-02T02:40:50", "published_display": "02 Jul 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Harrow, Inc. \u2013 NASDAQ:HROW", "summary": "The article provides financial information for Harrow, Inc. (NASDAQ: HROW), specifically its enterprise value to revenue forward. It appears to be a stub or a section from a larger financial data platform, showing the company's ticker, market, and a period-specific value with cha", "url": "https://www.tradingview.com/symbols/NASDAQ-HROW/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T00:47:37", "published_display": "02 Jul 2026 00:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harrow brings an interchangeable eye-drug biosimilar to U.S. retina care", "summary": "Harrow (Nasdaq: HROW) has launched BYOOVIZ (ranibizumab-nuna) in the U.S., an FDA-approved interchangeable biosimilar referencing LUCENTIS for various retinal conditions like Wet AMD. This launch, following an exclusive commercialization agreement with Samsung Bioepis, expands Ha", "url": "https://www.stocktitan.net/news/HROW/harrow-announces-commercial-launch-of-byooviz-in-the-united-jam75vn55hot.html", "source_name": "Stock Titan", "published_at": "2026-07-01T14:39:53", "published_display": "01 Jul 2026 14:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harrow Expands Retina Portfolio With US Launch of Byooviz", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/harrow-expands-retina-portfolio-us-120331323.html", "source_name": "MT Newswires", "published_at": "2026-07-01T12:03:31+00:00", "published_display": "01 Jul 2026 12:03", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A first FDA-approved eye biosimilar returns to U.S. sales", "summary": "Samsung Bioepis has relaunched BYOOVIZ (ranibizumab-nuna) in the US in partnership with Harrow, making the FDA-approved ophthalmology biosimilar referencing LUCENTIS available again. BYOOVIZ was the first ophthalmology biosimilar approved by the FDA in 2021 and received interchan", "url": "https://www.stocktitan.net/news/HROW/samsung-bioepis-relaunches-byooviz-ranibizumab-nuna-in-the-united-bqveabvqfqe4.html", "source_name": "Stock Titan", "published_at": "2026-07-01T11:11:37", "published_display": "01 Jul 2026 11:11", "sentiment": "positive", "sentiment_pct": 74, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Grow Funds\u2019 Exit and Weaker Earnings Recast Harrow\u2019s (HROW) Growth Narrative and Governance Choices", "summary": "Harrow, Inc.'s recent annual meeting approved director nominees and executive compensation, but Grow Funds' exit and disappointing earnings have cast doubt on the company's growth narrative. Investors are now more closely scrutinizing Harrow's ability to execute on product launch", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-hrow/harrow/news/how-grow-funds-exit-and-weaker-earnings-recast-harrows-hrow", "source_name": "Simply Wall Street", "published_at": "2026-06-25T23:09:33", "published_display": "25 Jun 2026 23:09", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harrow, Inc. Actuals & Estimates (NASDAQ:HROW)", "summary": "This article provides an overview of Harrow, Inc. (HROW) stock, including its current price, market capitalization, historical performance, and financial estimates. It details analyst forecasts, past earnings reports, future earnings dates, and revenue figures, emphasizing that t", "url": "https://www.tradingview.com/symbols/NASDAQ-HROW/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T16:09:12", "published_display": "25 Jun 2026 16:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HROW Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Harrow, Inc. (HROW) stock, including its current price, historical highs and lows, and analyst predictions for 2027. It also details financial metrics such as market capitalization, recent earnings, revenue, EBITDA, and upcoming earnings repor", "url": "https://www.tradingview.com/symbols/NASDAQ-HROW/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T14:41:11", "published_display": "25 Jun 2026 14:41", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harrow (HROW) director granted 5,248 restricted stock units as compensation", "summary": "Harrow, Inc. director Lauren P. Silvernail was granted 5,248 restricted stock units (RSUs) as compensation for her services. These RSUs will vest in equal quarterly installments over one year, contingent on her continued service with the company. The shares underlying these RSUs ", "url": "https://www.stocktitan.net/sec-filings/HROW/form-4-harrow-inc-insider-trading-activity-f57206ccfe0d.html", "source_name": "Stock Titan", "published_at": "2026-06-24T04:10:26", "published_display": "24 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GROW Small Cap Equity Fund Covered Its Position in Harrow (HROW) in Q1", "summary": "The GROW Small Cap Equity Fund covered its position in Harrow, Inc. (HROW) during Q1 2026, citing a disconnect between high street earnings expectations and the company's underlying growth. While the fund acknowledged Harrow's long-term potential, its conviction shifted towards A", "url": "https://www.insidermonkey.com/blog/grow-small-cap-equity-fund-covered-its-position-in-harrow-hrow-in-q1-1787389/", "source_name": "Insider Monkey", "published_at": "2026-06-23T08:06:00", "published_display": "23 Jun 2026 08:06", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Harrow Health Inc For: 22 June By Investing.com", "summary": "This article announces a Form 4 filing for Harrow Health Inc., dated June 22. It briefly mentions the company's stock symbol, HROW, and its -1.07% performance, alongside other financial market data and news headlines.", "url": "https://uk.investing.com/news/stock-market-news/form-4-harrow-health-inc-for-22-june-93CH-4739325", "source_name": "Investing.com UK", "published_at": "2026-06-23T00:40:51", "published_display": "23 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harrow (HROW) director Adrienne Graves receives 5,248 RSUs as compensation grant", "summary": "Harrow, Inc. (HROW) director Adrienne L. Graves has been granted 5,248 Restricted Stock Units (RSUs) as compensation for her services. These RSUs will vest in equal quarterly installments over one year, contingent on her continued service. The underlying shares will not be delive", "url": "https://www.stocktitan.net/sec-filings/HROW/form-4-harrow-inc-insider-trading-activity-ef98c155356c.html", "source_name": "Stock Titan", "published_at": "2026-06-22T23:40:51", "published_display": "22 Jun 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] HARROW, INC. Insider Trading Activity", "summary": "HARROW, INC. director Perry J. Sternberg reported the acquisition of 5,248 restricted stock units (RSUs) as compensation. These RSUs vest in equal quarterly installments over one year and will only be delivered as common shares after his service with the company ends. This transa", "url": "https://www.stocktitan.net/sec-filings/HROW/form-4-harrow-inc-insider-trading-activity-7906527569af.html", "source_name": "Stock Titan", "published_at": "2026-06-22T23:40:50", "published_display": "22 Jun 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 8K Harrow Health Inc For: 22 June By Investing.com", "summary": "This article reports on the filing of a Form 8K by Harrow Health Inc. for June 22nd. It provides the stock symbol HROW and mentions its current performance. The content is brief and serves primarily as an announcement of the filing.", "url": "https://ca.investing.com/news/stock-market-news/form-8k-harrow-health-inc-for-22-june-93CH-4700525", "source_name": "Investing.com Canada", "published_at": "2026-06-22T22:11:53", "published_display": "22 Jun 2026 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harrow elects directors and approves executive compensation at annual meeting By Investing.com", "summary": "Harrow, Inc. (NASDAQ: HROW) shareholders elected four directors to its board, approved executive compensation, and ratified Deloitte & Touche LLP as its accounting firm during the 2026 Annual Meeting of Stockholders. The company's shares have seen significant gains over the past ", "url": "https://za.investing.com/news/stock-market-news/harrow-elects-directors-and-approves-executive-compensation-at-annual-meeting-93CH-4337430", "source_name": "Investing.com South Africa", "published_at": "2026-06-22T22:11:52", "published_display": "22 Jun 2026 22:11", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harrow elects directors and approves executive compensation at annual meeting", "summary": "Harrow, Inc. (NASDAQ: HROW) held its 2026 Annual Meeting where shareholders elected four directors to the board, approved executive compensation on an advisory basis, and ratified Deloitte & Touche LLP as its independent accounting firm for 2026. The company has seen a 10% stock ", "url": "https://m.investing.com/news/sec-filings/harrow-elects-directors-and-approves-executive-compensation-at-annual-meeting-93CH-4752421?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-22T11:39:46", "published_display": "22 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harrow (HROW) investors back all 2026 director, pay and auditor proposals", "summary": "Harrow, Inc. shareholders approved all proposals at their 2026 annual meeting, including the election of four directors, advisory approval of executive officer compensation, and the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the", "url": "https://www.stocktitan.net/sec-filings/HROW/8-k-harrow-inc-reports-material-event-bd517e45a284.html", "source_name": "Stock Titan", "published_at": "2026-06-22T11:39:46", "published_display": "22 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spotlight On Harrow And 2 Other Growth Stocks With Strong Insider Backing", "summary": "This article highlights Harrow (HROW), Alphatec Holdings (ATEC), and AvePoint (AVPT) as growth stocks with significant insider ownership, suggesting strong confidence from management. Harrow, an eyecare pharmaceutical company, expects substantial revenue growth and future profita", "url": "https://simplywall.st/stocks/us/software/nasdaq-avpt/avepoint/news/spotlight-on-harrow-and-2-other-growth-stocks-with-strong-in", "source_name": "Simply Wall Street", "published_at": "2026-06-18T11:40:17", "published_display": "18 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harrow Inc (HROW) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Harrow Inc (HROW) holds a stable financial status with a score of 7.49, ranking 117th in the Pharmaceuticals industry. While its operating efficiency is high, the company reported a year-over-year revenue decrease of 7.59% and a significant net profit decrease of 55.24% in its la", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-hrow/financial-health", "source_name": "TradingKey", "published_at": "2026-06-17T09:40:05", "published_display": "17 Jun 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harrow Inc (HROW) Institutional Confidence", "summary": "This article analyzes Harrow Inc.'s (HROW) institutional confidence, noting its current shareholding score of 5.00, placing it 73rd out of 157 in the Pharmaceuticals industry. Institutional shareholding has increased to 66.17% quarter-over-quarter. Private Capital is the largest ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-hrow/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T09:11:04", "published_display": "17 Jun 2026 09:11", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can Harrow\u2019s (HROW) VERKAZIA Relaunch Redefine Its Niche Ophthalmic Strategy?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOZUpsSU9ScmQxNC1tMDVhZGJTZG14YllxSXVHYWs5bkF4QUM5YVNiVzZFQzNXWEk5T3hNTk1fTHNYRnQ1RFlqem9KSmdnWERudFZETThoWEZHREpYUHZnN3dCMUhxTEF1cVJOeElXVTVha0JfYS1kdmRDY05qdmJoQ0R4QUZraUR3c3NVYUIxaTZnNGJTRXZRZ2tFWkJSenhHLTFLTVJqQ2dtaDA?oc=5", "source_name": "Market source", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HROW Stock Rises on Relaunch of Ophthalmology Drug Verkazia in the US", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQalJfMUFSZ3BRUHNsdUZ3RmlqRWNHMnRFYXpCT2xWUDdNUW9WQS1Ba05nLVVaaEdZTkFGS01HTm9yMUlvWUo4MzBXQXc1SldiYUtYSXF1MDJkcTYwUk8ycHhXdHJCWGhWZWtmaUJBdWxvOW9adjAwOURtT2x5VHpPYUhRd3ZDeVNyYVhVT1lLNU5fLXBZQ05JbDhueGpzaVp0RUFQMGtsOXhFZ1V5cmZV?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harrow Re-Launches VERKAZIA\u00ae (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/harrow-launches-verkazia-cyclosporine-ophthalmic-110000502.html", "source_name": "GlobeNewswire", "published_at": "2026-06-10T11:00:00+00:00", "published_display": "10 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Does Cantor Fitzgerald Think About Harrow (HROW) After Cutting Its Price Target?", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/does-cantor-fitzgerald-think-harrow-214353759.html", "source_name": "Insider Monkey", "published_at": "2026-06-04T21:43:53+00:00", "published_display": "04 Jun 2026 21:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harrow to Present at William Blair\u2019s 46th Annual Growth Stock Conference", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/harrow-present-william-blair-46th-110000356.html", "source_name": "GlobeNewswire", "published_at": "2026-05-27T11:00:00+00:00", "published_display": "27 May 2026 11:00", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why B.Riley Reduced Harrow, Inc. (HROW) Price Target Despite Long-Term Optimism", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxOQy1DWHFQcFBfVWtxUHN3SG5sMFdQLVR2SGxFUjNwNFdYLWZRdk9FZVhfX3FWd0J0YlBkUGozLWgzTUczREhJNXZZc1VST3J4RS1MNkJQMk1ScWVrWHdfblFSRkExMGU5YzhfMy1LU0VVaDBHQXZMSU50WldHRXNsT0ZyZHZGdFpHVV9YVVJ0bGk4LUtYb3c?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Harrow (HROW) Narrative Is Shifting As Analysts Recut Targets Yet Stay Positive", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOdEFtdk1UMUxtTzJLaVdXYl9EY29xaXcyU1hfMzlqc2U4Ylp3bkpmTGFCOXJ0THByZkFfTWZObjVTcl9KYXBnN1dPaWFCRzZOX0h1TmtfQVZIbjVhUEM1YmMtemV0ZWxNRTA1ekZxSjJpSzY0UW5ZTkViZHk2Y1gwTEJLS1VXMXo2dGo1UXJvdGtUMm9mbU9BX0ZBSU9BbnFh?oc=5", "source_name": "Market source", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Opaleye entities report 7.61% stake in Harrow (NASDAQ: HROW)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxNZFdDTkZpdzBWOUdYeWtfNnUxeUoxWHZyUk5UQmh3UWJpWUo4cC1PX3FDVkhDZjl0cGx1eXNRemIxNkZHV0ljS0pNZEw2TzJaMjlHR1F1SnAzVXZUeVZERXFkRmJrLS1aLUs1SE1IdndyQ2QySDZ2Y3gycmJHMlFVWVVwcWd1N3ZWbWdXUHgxVWp4ZlZHaHRMUk1rVElFNWZ3QXJlckI1WmI0cTdfTkFjdXpFVDJlU2dheHJsZ0VLUDZvY0U?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harrow (HROW) Reports Q1 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOb2VzbU54QVdJUEhIUEJUSmNCWmhYS3ZsT1NUQkk5ZTlCWFhlRVdFQ0hieWNlalNWX2QyalZnVVRyVGFIZDJvcTJMLWVIZ0ZROXM5ZW84Z1FGNVF2Z25yTjBpUzd0UjVFdmZVUXZ0VXV1aVdQTVBmdjBRRWFBSXpyaXZWUmJSSDJvVnY2VGVwQzRWOVRwUVhYQVVoWFM?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harrow Inc. (HROW) stock falls on Q1 2026 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxOMXVqVWc1eHlqejRrNDJ3c2cwZ1ZNQXNKVUZhanp3SEtDM3FGQVhIdF93WVBzTF9ZZVh0b2RlaGlHNWNxSUNkZkNFbGJsVjEtUWJvd2cyYTdpQ3E5QmxTZGt5QVJfWWZhbDlNZTlRd1NadllyZmpLTUIxWjRJc0wtazZ2aENoTFFUTzRfRGY3aEI?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Harrow (HROW) Pricing Reflect Its 65.5% One Year Surge And DCF Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNelVNS01NUUU2amx5ZTE5eEJITjNpNlFSNjdmd1Y0NDI3QVpDdDY2LXVDNGdReVROeGVheWVzVU5iX1d0RnNIcGJaSmdkYUhSQk9DamFGb0hhclV5UHJfZGNrMVE1R2oyWFRoT0ZtNTRldVNkUUdwMEdFTHJmdU5UOXNvWWFlNlJRN29lZmVmYlZhUmhzbWFLUkNIQQ?oc=5", "source_name": "Market source", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harrow Inc (NASDAQ:HROW) Screens as a Strong Growth Stock with a Bullish Technical Setup", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxPNXFlbzFYZ0paM2hlRjg4YW9TWjQ3YlBkdm03emRYZWh1Z2RtSWZGUEFmajVZVFJrMEJ1UHp5OWhsRkVnS0JyLXptTFBNc0lxZTZXVXNrVG0yM2psMEpmbW1XS0h0d1ItYmNvOWFvc0VUbDBBX2RXMFQ4YS1lNjJNM3JqY3lFbDBVeDZmbm5oRTI3dmxybk52NDRaRnN1T3Y5Y3JSaEZlck9BN3RXV3FLNDFLR3ZHR0d1VzNQYTBCdEtnN3lUa0hKOXJMSUlqZ0ZUUXpJ?oc=5", "source_name": "ChartMill", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 95, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Estimate Harrow (HROW) to Report a Decline in Earnings: What to Look Out for", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQZWl6LXZuTVc5b2dFRTdfTGViNUZWTi1DTGhWaEZKc1l4WE4zLVdyM1FjTi0zc1lqUTdGOF9LSF9Nb1JLamJDUFFhcXNyLUFrMTg0MFVQbHRDc2hHYjNBT3dOV2xxS05JNXRFTW5zQmp4WW5RTW9DR1Y2VVhZV3hWdFRkb0oxNk8wQ3A3UFdhYTBfS01XRXhjQk5tV2VtY3MxVjNz?oc=5", "source_name": "Market source", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Harrow, Inc. (HROW) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxONDFMWlhjRkExd003OFA0b2xGN1I3cFQyWGFIYUtZb1pCODctclBhdzZZVnBjU2dKSVFlSEc3NDYwa3hBODVZLXhnczJEZ1ZxTzhGQnVBWEVsMkw2VU9sUE05b3lqSUhMeWRnZ24yTFpsSUJXNzYzb1kxbWRGU1pSZTJBUFFWc3JDbThoVV84X1dIWFZuYkE?oc=5", "source_name": "Market source", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harrow shifts U.S. eye drug distribution to LogiCare3PL in 4 weeks", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNVDdVZWRyNGtkY0k0TjdTTzJTVERFSlVva000MjBJX1NGd3lYR0d4RXMtZjQyZnIzN3pfaDZmRGhBWmNkVmpsNXNwM2pyMC1hb0tESnd5LTlXaTRwOHNEUDlMLVhraGVNMGF6MUlSZmdYby1MYWhZWEhWcHB6NVNLQjg5dEdzRmpMU3FFR2ZRR2o2cy1oQ05qdTl0T1lPdEoxaW5oZzln?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Health Insurance Providers Stocks\u2019 Q4 Earnings: Alignment Healthcare (NASDAQ:ALHC) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNT01mVGxMZ0dTU1BFZll2Wm5Bekc1STJkajdhWGFYMmJGUktiVFZGN2k4b3ZobDNVbW5IejF6dGZYWERRR1g0aHhrcUJnZ09PeU1sb3FISTZjWjlVMmFMMEhVdERvU0k0a2tIQmhkSTB4bzFaN1NYbi1xekk1OHk5TE82WlpkVmVHZ2VNY25OejQ2MHhsRVNsbngydG5Rd29TcmJuLVI3YlU?oc=5", "source_name": "Market source", "published_at": "2026-04-03T07:00:00+00:00", "published_display": "03 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HARROW INC (NASDAQ:HROW): A GARP Stock with Strong Growth at a Reasonable Price", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPd204aGxqTzlERDY0dWFURFpBNnZia3lVU1dQeHZ6VXdIQ2o5UmNtcVNKWlY0M0V6RkxMT1JaR1JHMjI1aFYwSVZFVVkyTEJyTE94c21zSGpDcVBRYnpGNVE4TFJjb2FYTGZnNDJLWEhTcFBsTEZLWWV3THYzSUpGd0ctcFQyYnQ1UEZtb2tMVDk1cS0zQmc3Tno3Rmd0R3pSNzM3VjNUWGp3SXk4bzVicU1WMW1MNnAzYXprZWtndHRQSjJCUXc?oc=5", "source_name": "ChartMill", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harrow (HROW) Misses Q4 Earnings Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxNcTFoTjMyYWRpX2xhLU1MRWVSVmlTbUhON0JSZVo0cjdkdVUxWjVJbWNMTEU1aW1CX0dpSGNHNEJMVmcwLVVYSmwxbGtkSFNaeWR5OHdRYUVoSnFCUWdLRDdSeEIwbmNnX01NekJRS1N0NjVWdFc4aUpORXFUdWg2dFJn?oc=5", "source_name": "Market source", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harrow Inc. (HROW) Stock Falls on Q4 2025 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxOZ2hzZWJmamE2S05DUDN5c1FvTHlTcVdiX0dCZVN0aTg5MlVqRXJDeVo0bk1NcUo3WEI5OVJ2enBRVk54eHc3cldGYkNibnRydU5uUnk1ZXhCWGRTZ1dMNHdnWVh6Tm15Smo1Y2pPN250MUFUYnMyY2ZKdHdxZU9PTFBTdnY0NHhlZkU3cUdqZjM?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harrow Announces Availability of Fortisite\u2122 Formulations for In-Office Use", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOc2Vibk1tSzVJNG9RbVhaVkxDcWdMNWZOQjFLTzRjdGpvV3czR1pwcmZGTVVqeUpJdVJwOXhnMEUtMG5BNlJHblNLWFJWNS1JYnFXRGZyVzhIc0V6TzNNUlYyUnlwbHdMY0ZCNHBGU1N5bHh4OUx2bGFiNjdEWjVzT195NUpOakZCNENCNlpkVTY0MDc0dGY2S21vX3FGc1RBYnN5T1drSUROMVNqekxXcXItT2ZsZWQwTERjdDRUNDFoT21xRDktTTVB?oc=5", "source_name": "Business Wire", "published_at": "2023-01-05T08:00:00+00:00", "published_display": "05 Jan 2023 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harrow Secures Capital to Close Recently Announced Acquisition", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOWndtLTZpUThTYVU4T043cG9fcFVHTHR4ZTd4MUhVRVdRUWxxdDgyY0F1RWNtMGF5eV9UdzJ2cEk4V1E4U0tKU09CZFYwaTFaWi1pajBlaEVGZjhPbHYwU2pJUkZ3bnJodDF5X21HN3JzOGhHTkY1ZjZ4X21zdk5Sb09VX3FCWmRpTG5GeWFzN1Q2RWRMS1lWWldSeGt1N1BseDNsUkNyakxnUFFkLTdZbTNvV2x6cm9qc01R?oc=5", "source_name": "Business Wire", "published_at": "2022-12-16T08:00:00+00:00", "published_display": "16 Dec 2022 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harrow Health Announces Second Quarter 2022 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQaWRhQTdmSF85Ri13U3hwcHdxVVJxUDF2UjJORWtVVjlteUpUZUxiS2hidzZNa01NbHRPdWtJX1RrbmdOS0dQcmwwb2VSUVNOUzhPMVIxMnRnZXk2WDd3aUEydDU3U0lyVVU3VFNCNndXQ3dDNEdwdDJtdmZfdHVmLXB3MlRaOHdKZ2ttLTQxeTU4RjVhb1VKMzhUMDAyRFFQQWRzejRac3VBM01fUmhSVVFuQ2tRUU9uY2c?oc=5", "source_name": "Business Wire", "published_at": "2022-08-09T07:00:00+00:00", "published_display": "09 Aug 2022 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harrow (HROW) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE5HaW44bC1xNUpTRDNLU0Z1bWdqNDhWQWlSNGpsRWpEVnZ3VUtiY1Y3amw4UjhLTHJ6S3F2UVNwM2R4V0h5dU1vYzhYaVRybDRzcVRzT1owbjJPUQ?oc=5", "source_name": "MarketBeat", "published_at": "2019-02-02T02:56:21+00:00", "published_display": "02 Feb 2019 02:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 78, "total_relevant": 53, "sentiment_summary": {"positive": 17, "negative": 7, "neutral": 29, "score": 54, "total": 53, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 14.65, "count": 26}, {"event": "earnings", "label": "Earnings", "weight": 8.8, "count": 16}, {"event": "deals", "label": "Deals and strategy", "weight": 3.3, "count": 6}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.9, "count": 1}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 17, "negative_events": 7}, "market_context": {"has_market_context": true, "latest_close": 42.48, "latest_week": "2026-07-10", "one_week_move": -0.6, "four_week_move": 12.9, "twelve_week_move": 2.4, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.734508, "market_dynamics_buy_signal": false, "relative_strength": -10.328959, "fair_value_gap": 43.5, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 55.4949, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-0.6% over one week, +12.9% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 52, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 9}, {"label": "Stock Titan", "count": 8}, {"label": "TradingView", "count": 7}, {"label": "Business Wire", "count": 4}, {"label": "Simply Wall Street", "count": 2}, {"label": "Insider Monkey", "count": 2}, {"label": "TradingKey", "count": 2}, {"label": "GlobeNewswire", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 53}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 26}, {"label": "Earnings", "count": 16}, {"label": "Deals and strategy", "count": 6}, {"label": "Analyst action", "count": 2}, {"label": "Balance sheet", "count": 1}, {"label": "Regulatory and legal", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "53", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-0.6% over one week, +12.9% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Harrow Inc (HROW) Shares Surge 3.9% -- What GF Score of 81 Tells Investors"}], "updated_at": "2026-07-16T14:31:05.940963+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}